Novo Nordisk escalates lawsuits against US companies selling cheaper Wegovy copies, except Hims & Hers.

Novo Nordisk is suing US companies selling cheaper versions of its weight-loss drug Wegovy, except Hims & Hers. Despite a June accusation of violating intellectual property, Novo may pressure Hims to negotiate instead of pursuing litigation. The drugmaker has filed over 130 cases in 40 US states and hasn't ruled out further action against Hims.

Novo Nordisk, a leading Danish pharmaceutical company, has been actively pursuing legal action against numerous U.S. pharmacies and companies selling cheaper versions of its weight-loss drug Wegovy. However, one prominent telehealth company, Hims & Hers, has thus far been excluded from these legal efforts despite a prior accusation of intellectual property violation. This strategic move by Novo Nordisk could potentially pressure Hims & Hers to negotiate rather than face litigation.

Novo Nordisk has filed over 130 lawsuits in 40 U.S. states, targeting small pharmacies, telehealth providers, and weight-loss clinics. These lawsuits allege trademark infringement and the promotion of compounded versions of Wegovy, which are sold at lower prices. The drugmaker has not ruled out further legal action against Hims & Hers but has not yet confirmed any specific litigation against the company.

Hims & Hers, which offers personalized versions of Wegovy, has defended its practices, arguing that individualized dosing remains legal under compounding rules. The company has maintained that its platform allows patients and providers to make clinical decisions, positioning personalized medicine as the future of healthcare.

Legal experts suggest that Novo's expanding litigation against smaller telehealth players could add pressure on Hims & Hers to negotiate a settlement or help the drugmaker test out strategies. The fact that Novo and Hims had a prior collaboration may complicate legal action, with some experts noting that business often happens in the shadow of the law.

In addition to these legal developments, Novo Nordisk is also facing a pending class action lawsuit. The Gross Law Firm has reminded shareholders of the pending class action lawsuit with a lead plaintiff deadline of September 30, 2025. The lawsuit alleges that Novo provided misleading statements about its growth potential and the impact of compounded GLP-1s on its sales.

The ongoing legal battles and potential settlements could have significant implications for both Novo Nordisk and Hims & Hers. Investors are advised to monitor these developments closely, as they may impact the financial performance and stock prices of both companies.

References:
[1] https://www.reuters.com/legal/litigation/novo-nordisk-ramps-up-lawsuits-over-wegovy-copies-investors-ask-where-is-hims-2025-08-11/
[2] https://www.morningstar.com/news/pr-newswire/20250811ny47875/the-gross-law-firm-reminds-novo-nordisk-as-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-30-2025-nvo
[3] https://www.nasdaq.com/press-release/hims-hers-health-hims-investors-august-25-2025-filing-deadline-securities-class-4